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According to the protein-only hypothesis, infectious mammalian prions,
which exist as distinct strains with discrete biological properties, consist of
multichain assemblies of misfolded cellular prion protein (PrP). A critical
test would be to produce prion strains synthetically fromdefined components.
Crucially, high-titre ‘synthetic’ prions could then be used to determine the
structural basis of infectivity and strain diversity at the atomic level. While
there have been multiple reports of production of prions from bacterially
expressed recombinant PrP using various methods, systematic production of
high-titre material in a form suitable for structural analysis remains a key
goal. Here, we report a novel high-throughput strategy for exploring a
matrix of conditions, additives and potential cofactors that might generate
high-titre prions from recombinant mouse PrP, with screening for infectivity
using a sensitive automated cell-based bioassay. Overall, approximately
20 000 unique conditions were examined. While some resulted in apparently
infected cell cultures, this was transient and not reproducible.We also adapted
published methods that reported production of synthetic prions from recom-
binant hamster PrP, but again did not find evidence of significant infectious
titre when using recombinant mouse PrP as substrate. Collectively, our find-
ings are consistent with the formation of prion infectivity from recombinant
mouse PrP being a rare stochastic event and we conclude that systematic gen-
eration of prions from recombinant PrP may only become possible once the
detailed structure of authentic ex vivo prions is solved.1. Introduction
Prions are infectious agents responsible for the transmissible spongiform ence-
phalopathies or prion diseases, lethal neurodegenerative conditions including
Creutzfeldt–Jakob disease in humans, scrapie in sheep and goats, bovine spongi-
form encephalopathy in cattle, and chronic wasting disease in deer and elk [1,2].
Prions are thought to consist of fibrillar polymers of misfolded cellular prion
protein (PrPC) that propagate by recruitment of host PrPC leading to elongation
and fission [3]. It is increasingly thought that prion-like processes, with the
spread of propagating proteopathic seeds, underlie the pathogenesis of more
common neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, lead-
ing to a wider interest in understanding prion structure and strain diversity [4].
Historically, it has proved difficult to adequately purify ex vivo prions and
obtain sufficiently homogeneous material for high-resolution structural analysis;
hence the structure of infectious prions and the structural basis of prion strain
diversity remain unresolved. The ability to make synthetic prions, at will, from
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Figure 1. Plate format for matrix core conditions. Master 96-well plates were
prepared so that wells contained a- or b-PrP at a final protein concentration
of 0.01 or 0.1 mg ml21 in a fixed set of core solvent conditions of defined
pH and concentration of DTT and NaCl. Condition variables and additives
(table 1) were introduced to this master plate format, after which plates
were incubated for different time periods at different temperatures (as
detailed in Methods) prior to infectivity measurement in the ASCA.
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protein-only hypothesis beyonddoubt, butwould also provide
a model systemwhere the assembly mechanism and structural
properties of the infectious agent could be elucidated. Were
relatively homogeneous prions produced from recPrP, it
would be expected that they could be diluted many million-
fold and still result in 100% lethality in susceptible animals
[3]. In the absence of such results, structural studies would
be futile (and indeed would report on the large excess of
uninfectious material [3]).
Early reports of structural conversion of the predominantly
a-helical PrPC conformation to isoforms with properties in
common with disease-associated forms (PrPSc) isolated from
infected tissue [5–9] were not accompanied by evidence of
infectivity. However, there have since been multiple reports
of de novo production of prions from bacterially expressed
recPrP using a range of methods [10–14]. Interpretation of
some of these reports is complicated either by bioassay using
transgenic mice with high levels of overexpression of PrP
(which develop spontaneous neurodegeneration) or by use of
in vitro prion amplificationmethods such as proteinmisfolding
cyclic amplification (PMCA), which are capable of amplifying
a single prion particle to a concentration that can be detected in
rodent bioassay, leading to concerns of contamination or
amplification of naturally occurring prions that might form
spontaneously in mammalian brain with a low stochastic fre-
quency [15]. Importantly, however, none of these studies
have reported a systematic method for production of large
quantities of high-titre material that would be suitable for
detailed structural analyses.
In our own earlier work, while we did occasionally observe
neurological disease in rodents challenged intracerebrally with
various preparations of recPrP which could be passaged, we
were unable to do this reproducibly and concluded that if infec-
tivity were produced in these experiments at all, it was of
extremely low titre and useless for structural characterization.
Optimization of prion synthesis via lengthy rodent bioassay
massively restricts the range of conditions that can be tested,
and for this reason we established a novel strategy to allow
rapid exploration of a large array of conditions, additives and
potential cofactors in a manner conceptually similar to a
matrix approach to protein crystallization and rapidly screen-
ing for infectivity using a cell-based prion bioassay, the
scrapie cell assay (SCA) [16], which we have automated
(ASCA) and used for high-throughput prion determination
[17,18]. It would then be possible to focus on a subset that
could be iteratively optimized to produce high-titre prions
that could be investigated further. A further advantage of
using a cell-based system to detect synthetic prions is that nas-
cent prions may be particularly labile and sensitive to in vivo
clearance and other defence mechanisms. Conversely, it
might be argued that the ASCA is limited to detection of
RML or 22 L-like prions [16]. However, prion strains appear
to constitute amolecular ensemble or quasi-species in dynamic
equilibrium [3,19]. The population of different strains must
follow statistical thermodynamic distributions with varying
energy barriers between them. Even where the barriers may
be high and rates of inter-conversion slow, there is clear evi-
dence for the coexistence of several conformations which can
evolve under selection [20] such that PK1 cells may select
RML-like prions via conformational selection [3,21]. That the
RML prion strain can be derived by single passage of cattle
BSE prions in SJL inbred mice also suggested RML may be aparticularly preferred pathogenic PrP conformer in mice [22].
Notably, synthetic prions generated by Ma and co-workers
[14] could infect cells in culture but produced a non-RML
prion strain phenotype when subsequently inoculated in mice.
These findings support the ability of cell culture infectivity
assays to detect infectious prions with novel strain properties.2. Results
Prior to design of thematrix of conditions to be explored, a com-
prehensive characterization of the biochemical properties and
physical stability of ex vivo RML prions was performed (data
not shown). Additional conditions were added in response
to published data on putative cofactors [11,12,14,23,24].
We conducted an unprecedented search for conditions that
could produce high titres of synthetic infectivity in a reproduci-
blemannerwith defined solvent and environmental conditions.
To achieve this, recPrP folded into a native alpha-helical
conformation (a-PrP) of a beta-sheet-enriched conformation
(b-PrP) [5] was exposed to differing solvent conditions varying
with respect to pH, redox potential and ionic strength. The
variables chosen were designed to manipulate the making
and breaking of disulfide bonds, the net protein charge, the
strength of electrostatic and non-polar interactions, and the
rate of protein–protein collisions. These variable solvent con-
ditions were replicated with extending incubation times of 1 h,
overnight and three months, with further nested variation of
temperature comprising room temperature, 4, 37 and 558C.
These ‘core’ conditions were explored on 96-well plates
(figure 1)with the incorporation of conditionvariables andaddi-
tives (table 1), based upon previous reports in the literature or
rational consideration of what may promote ordered aggrega-
tion events and relevant cofactors. The secondary variables
included proteolysis (to enrich the proportion of resistant
material), brain homogenate (to supply cofactors), phospholi-
pids/detergents, scaffolding factors (e.g. heparin) and metals
that may affect the folded conformation. We specifically
explored the effects of reaction surfaces, notably stainless steel,
given previous findings that prions can be efficiently concen-
trated on steel wires, allowing greatly enhanced prion
Table 1. Condition variables and additives applied to the core matrix.
variable condition detailsa
limiting proteolysis 0.1 mg ml21 proteinase K, 378C, 30 min
1.0 mg ml21 thermolysin, 378C, 30 min
reaction surface discs (surgical steel, AISI 304, 316)
wires (surgical steel, AISI 304, 316)
polypropylene, polycarbonate, glass, PTFE
additives detailsa
Pro-ject
lipids
commercial transfection reagent
anionic/cationic mixes
silk, heparin,
glycogen, ferritin
protein scaffolds
surfactants 0.1 and 5.0% (w/v) SDS
0.1 and 1.0% (v/v) Triton X-100
0.1 and 1.0% (v/v) Tween-20
metal ions Cu2 þ at 1 : 1 and 5 : 1 molar ratio to PrP
Zn2þ at 1 : 1 and 5 : 1 molar ratio to PrP
Mn2þ at 1 : 1 and 5 : 1 molar ratio to PrP
brain or cell
homogenate
1.0% (w/v) normal mouse brain
PMCA substrate normal mouse brain
PK1 cell membrane fraction
GuHCl denatured RML-infected mouse brain
previously reported PolyAdenosine [11]
1-palmitoyl-2-oleoylphosphatidylglycerol [14]
Phosphotidylethanolamine [24]
ﬁbrils recPrP ﬁbrils generated from RML
prion-seeded polymerization reactions
aFull details can be supplied on request.
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Figure 2. ASCA measurement of RML prion infectivity. (a) Dose– response
curve of RML prion infection of tissue culture wells containing 18 000
PK1/2 cells. The number of mouse intracerebral LD50 units of RML prions
applied per well is plotted against mean spot number per well+ s.e.m.
(n ¼ 6) determined at the fourth cell split. (b) Representative examples
of positive and negative ELISPOT wells.
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[15].Wealso investigated fibrils generated fromrecPrPbyadapt-
ing published methods which reported infectivity [10,26]. Prion
infectivity was assayed using a modification of the ASCA. A
serial dilution of a titred RML prion homogenate was assayed
in parallel as a positive control and for quantification of any
potential synthetic prions (figure 2). Samples were considered
positive on the basis of three criteria: (i) the presence of a high
number of PrPSc-positive cells (defined by protease-resistant
PrP deposits or ‘spot’ counts; see the electronic supplementary
material, Methods;.background mean þ 10 s.d.), (ii) evidence
of prion propagation (increasing number of positive cells over
two successive splits) and (iii) the reproducibility of duplicates.
Positive and negative controls were crucial for quality
control and their values had to fall within a validated range
(non-infected cells producing a background below a defined
threshold; see Methods) or the experiment was repeated. If
any positives were reproducible, the pooled conditioned
medium produced by the apparently infected cells was
assayed by SCA. In parallel, PrP-silenced PK1 cells, whose
Prnp expression was silenced by two shRNAs directed against
the 30-UTR and which are refractory to prion infection [27]
(electronic supplementary material, figure S1), were infected
with the same conditions to exclude the possibility of false
positives resulting from recPrP aggregation. If the repetitionexperiment was successful, the formation of putative synthetic
prions was assessed by standard mouse bioassay using
wild-type FVB/N mice. In total, we screened 19 468 unique
conditions (approx. 25 000 including repeated conditions).
Positive wells were recorded using our stringent criteria
from 480 unique conditions (electronic supplementary
material, table S1). These positive wells had the characteristic
visual appearance seen in our extensive experience of prion
bioassay by SCA; indeed, they were indistinguishable from
RML prion-infected positive control wells (figure 3). How-
ever, despite multiple attempts, we were not able to serially
propagate such isolates in PK1 cells. Furthermore, the con-
ditions were not reliably reproducible to enable large-scale
repeats to harvest cells for conventional mouse bioassay.
In addition to systematic screening of this matrix of con-
ditions, we also adapted specific published methods reported
as producing synthetic prions [10,12–14], including those
that relied on initial seeding with authentic ex vivo prions.
In common with others [28], we did not find evidence of
significant titre in the materials generated by these methods
(either by ASCA or by conventional mouse bioassay; electro-
nic supplementary material, table S2). To date the prion-seeded
• Cu : PrP 5 : 1 molar ratio
• RT immediate
• 0 mM Nacl
• 1 μg ml–1 Prp alpha
• pH 7.5
• Cu : PrP 5 : 1 molar ratio
• RT immediate
• 0 mM Nacl
• 10 μg ml–1 Prp alpha
• pH 3.5
wells A3
positive wells matrix 25c plate 3
wells A4 
split 3 split 4 split 5
Figure 3. Example positive wells from the matrix. ELISPOT wells containing spots with the characteristic visual appearance seen in prion bioassay by SCAwere observed to
increase successively over cell splits three to five. The matrix conditions that generated these positive findings are detailed next to the wells and were observed in the
presence of copper ions at a 5 : 1 molar ratio with PrP and incubation at room temperature (RT) for 1 h (immediate) prior to inoculating the cells. These findings were not
consistently reproducible.
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Supattapone and colleagues [29] represents the only preparation
with a specific infectivity that might be compatible with mean-
ingful structural analyses. However, the prion seed used to
initiate these reactionshasonlybeengeneratedby these research-
ers to date [14,29,30] and our own attempt to generate such a
prion seed by adapting their publishedmethods [14]was unsuc-
cessful (electronic supplementary material, table S2). In this
regard, the method has been reported by the authors to not
always lead to the formation of infectious prions [30].
Our own observations of occasional positive wells in
ASCA and the sporadic reports of synthetic infectivity in
the literature are consistent with the formation of infectivity
being a rare stochastic event which is difficult to reproduce
in vitro. Under our matrix conditions, the ASCA is able to
robustly detect prions at a concentration of 10 LD50 units
per 300 ml assay well (figure 2). For the highest concen-
trations of recPrP analysed (100 mg ml21 reactions), each
ASCA well contained 2.67 mg of PrP, which is equivalent to
the PrP content of 50 mg of RML prion-infected mouse
brain that contains approximately 108.1 intracerebral LD50
units. As the ASCA robustly detects as little as 10 LD50 units
per well our assay sensitivity has the ability to detect prions
at 1 part in more than 10 million of total PrP by weight. The
rare events that led to positive wells produced at best minimal
titres of infectivity and the inability to reproduce positivity in
such conditions precluded iterative optimization of conditions
in the hope of progressively increasing titre towards the aim of
generating material suitable for structural study.3. Discussion
Our findings, systematically screening unprecedented numbers
of conditions, highlight the difficulty of producing synthetic
prion infectivity from bacterially expressed recPrP. It is possi-
ble that efficient prion production requires eukaryotically
expressed, post-translationally modified PrP and/or specific
cofactors. Additional factors may also include specific biologi-
cal replication sites or surfaces. Highly specific quaternary
structural features may be required in PrP polymers to render
them efficient in vivo pathogens that would form at extremely
low probability in vitro. While it is possible that such rareprion assemblies would then be amplified in a biological
system, as may have occurred transiently in the SCA and
robustly in some published in vivo studies, this of course then
leads to the same problem of purification prior to structural
analysis that has limited progress with conventional prions.
One important caveat of our screening approach for syn-
thetic prions is that we are necessarily limited to detecting
prion strains with replication rates that not only exceed
their rates of degradation but also exceed the rate at which
PK1 cells divide [16]. Increasing the number of cell passages
beyond the standard SCA format would not therefore
improve the assay’s sensitivity or its ability to detect a greater
range of possible synthetic prion strains. Instead alternative
cell types that have different rates of division in culture
might be required in order to detect slowly replicating syn-
thetic prion strains [31]. However, repeating the screening
that we describe with different cell types would be a highly
challenging undertaking. A more promising approach may
come from progress with purification and structural charac-
terization of ex vivo prions [32], and in understanding
cofactors present in normal brain tissue necessary for efficient
in vitro prion amplification. These data can then be used to
guide more focused approaches to eventually produce homo-
geneous synthetic prions that would allow atomic resolution
structure determination.4. Material and methods
4.1. Research governance
Work with prion-infected samples was conducted in micro-
biological containment level 3 facilities with strict adherence
to safety protocols.
4.2. Preparation of recombinant prion protein master
plates
Recombinant mouse PrP (Prnp allele a, residues 23–231) was
prepared and folded in a native alpha-helical conformation
(a-PrP) or a beta-sheet-enriched conformation (b-PrP) using
buffer conditions described previously [33]. Full details can
rsob.royalsocietypublishing.org
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were dialysed into 10 mM bis-tris buffer (pH 6.5) or 10 mM
sodium acetate buffer (pH 4.0), respectively, and then adjusted
with the cognate buffer to give a final protein concentration of
1 mg ml21. Immediately prior to use 1 mg ml21 solutions were
diluted to 0.02 or 0.2 mg ml21 protein with 10 mM bis-tris/
10 mM sodium acetate buffer adjusted to pH 3.5, pH 5.5 or
pH 7.5. Master plates (Corning 96-well flat bottommicroplates;
Fisher Product Code: 10687551) were prepared so that wells
contained a or b PrP at a final protein concentration of 0.01
or 0.1 mg ml21 in a fixed set of core solvent conditions
(figure 1) in the presence or the absence of variable additives
(table 1) and a total final reaction volume of 80 ml. This was
accomplished by adding 40 ml of 0.02 or 0.2 mg ml21 a- or
b-PrP to each well followed by appropriate additions of salt
(2.4 ml of 5 M NaCl in water, to give 150 mM final concen-
tration), DTT (2.5 ml of 32 or 960 mM DTT prepared in water,
to give 1 or 30 mM final concentration) and additives (variable
volumes), after which water was added to give a final reaction
volume of 80 ml.Master plateswere sealed and incubatedwith-
out agitation for 1 h (immediate) or 16 h (overnight) at varying
temperatures (48C, room temperature, 378C and 558C). Some of
the reactions were also examined after three-month incubation
at 48Cor room temperature. At the end of the incubation, plates
were unsealed and 220 ml tissue culture medium (OFCS; see
below) added to each well and thoroughly mixed using a
Biomek FX liquid handling robot to give a final volume of
300 ml. A total of 100 ml aliquots from each well were then
directly applied to prion-susceptible cells (see below).4.3. Automated scrapie cell assay
Prion-susceptible PK1/2 cells (a line derived from N2a cells
that are highly susceptible to RML prions [16]) were routinely
grown in OFCS medium (Opti-MEM, containing 10% fetal calf
serum; 100 U ml21 penicillin and 100 mg ml21 streptomycin;
Invitrogen, UK) using 15 cm Petri dishes. Harvested cells
were manually dispensed into 96-well plates (Costar flat
bottom 96-well plates; Corning, UK) at a density of 18 000
cells per well 24 h prior to infection and kept at 378C in a 5%
CO2 incubator. The following day the cell medium was
removed and replaced with 200 ml fresh OFCS, after which
100 ml of the reaction solution from the PrP master plates
(see above) was applied using a Biomek FX liquid handling
robot. To verify the susceptibility of each batch of PK1/2 cells
to prion propagation, an additional plate of cells was treated
with 10% (w/v) RML-infected mouse brain homogenate
(serially diluted threefold in OFCS in the range 3  1025 to
1  1027) and processed in parallel. After 3 days of infection,
cells were resuspended using the Biomek FX, after which
37.5 ml of cell suspension from each well was transferred into
a new 96-well plate containing 262.5 ml OFCS (1 : 8 split) and
cells grown to confluence for 3 days. After two further 1 : 8
splits (as described above), an aliquot of 85 ml of cell sus-
pension from each well (containing approx. 25 000 cells) was
transferred into ELISPOT (Multi Screen Immobilon-P,
Millipore, UK) plates while a second aliquot of 37.5 ml cell
suspension was transferred to new a split plate containing
262.5 ml OFCS. This procedure was repeated for two further
1 : 8 splits. At the time of their collection, ELISPOT plates
were vacuum drained and dried at 508C prior to storage at
48C until further processing.4.4. ELISPOT plate development
Stored ELISPOT plates were warmed to room temperature,
after which 60 ml of 1 mg ml21 proteinase K (PK) (Roche, UK)
in lysis buffer (50 mM Tris HCl, pH 8 containing 150 mM
NaCl, 0.5% (w/v) sodium deoxycholate and 0.5% (v/v)
Triton-X 100) was added to each well and incubated for
60 min at 408C. The plates were washed (2  160 ml PBS) after
which 120 ml of 3 M guanidinium thiocyanate prepared in
10 mM Tris HCl pH 8.0 was added to each well for 20 min.
The wells were washed (7  160 ml PBS) and 150 ml of Superb-
lock dry blend blocking buffer (Perbio, UK) was added to each
well and incubated for 1 h. Following vacuum removal of
Superblock each well was incubated with 0.55 mg ml21 anti-
PrP monoclonal antibody ICSM18 (D-Gen Ltd, London)
prepared in TBST (10 mM Tris HCl, pH 8, 150 mM NaCl,
0.1% (v/v) Tween-20) containing 1% (w/v) non-fat dry milk
for 1 h. After washing (5  160 ml TBST), wells were incubated
for 1 h with 60 ml goat anti-mouse alkaline phosphatase-
conjugated anti-IgG1 (Southern Biotechnology Associates,
USA) diluted 1 : 8000 in TBST containing 1% (w/v) non-fat
dry milk. Following washing (5  160 ml TBST), wells were
incubated for 35 min with 50 ml AP dye (Bio-Rad, USA). The
plates were then washed twice with water, dried and stored
at 2208C. Spot counts (reporting PK-resistant PrP-positive
cells; see below) were determined with a Zeiss KS ELISPOT
system (Stemi 2000-C stereo microscope equipped with a
Hitachi HV-C20A color camera, a KL 1500 LCD scanner and
WELLSCAN software from Imaging Associates, Oxfordshire,
UK) as described previously [16] or more recently using a
Bioreader 5000-Eß system (BioSys, Karben, Germany).
4.5. Quantifying prion titre
ELISA detection of protease-resistant PrP on prion-infected
cells on ELISPOT plates results in the appearance of focal
PrP deposit ‘spots’ that have a morphological appearance dis-
tinct from any non-specific background immuno-reactivity
seen on the plate. A spot identifies when a prion-infected
cell and spot count within a defined population of cells is
proportional to the prion titre of the sample used to infect
the cells, with spot counts rising (as prions propagate) over
successive cell splits [16]. The dose response is dynamic
between approximately 50 and 1000 spots per well; however,
because the assay is nonlinear, every experiment must
include concomitant assay of a serial dilution of RML
prions of known prion titre (intracerebral LD50 units/ml
determined from rodent bioassay) to produce a standard
curve that unknown samples can be calibrated against. Two
stock pools of 10% (w/v) RML brain homogenate (desig-
nated I6200 and I8700) were used as reference preparations
and showed comparable prion infectivity titres in the scrapie
cell end point assay [16] of approximately 106.5 tissue culture
infectious units (TCIU)ml21 in PK1/11 cells [32,34,35] or 107.7
TCIUml21 in PK1/2 cells [18]. I6200 reported a prion titre of
107.3+ 0.5 (mean+ s.d.) intracerebral LD50 unitsml
21 when
endpoint titrated six times in Tg20 mice [32] that overexpress
mouse PrP on a Prnpo/o background [36] and I8700 reported a
prion titre of 107.2 intracerebral LD50 units ml
21 when endpoint
titrated once in Tg20 mice [32]. Figure 2 exemplifies a standard
curve generated by the ASCA, showing robust detection of
spots after infecting PK1/2 cells with 10 intracerebral LD50
units of RML prions per well. Matrix samples were scored
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(.backgroundmean þ 10 standard deviations), (ii) evidence of
prion propagation (increasing spot counts over two successive
cell splits measured between splits three and five) and (iii) the
reproducibility of duplicates for each sample.
4.6. Silencing of Prnp expression in susceptible
N2a cells
To silence Prnp expression in susceptible PK1 cells, the 19mer
TAGGAGATCTTGACTCTGA was cloned into the vector
pSUPER.retro.puro (Oligoengine). Sense and antisense target
sequences, flanked by a hairpin, TTCAAGAGA, were inserted
at the BglII and HindIII sites of pSUPER.retro.puro essentially
as described previously [27].
4.7. Adaptation of previous methods reporting synthetic
prion generation
Recombinant murine PrP encompassing the complete amino
acid sequence of the mature protein from residues 23 to 231
(PrP23–231) of Prnp allele a, or a truncated form representative
of the structure C-terminal domain PrP91–231, were subjected
to amodification of conditions previously described to generate
synthetic prions. In the case of material produced by Legname
et al. [10], the construct PrP91–231 was used and fibrillized at
0.5 mg ml21 in 20 mM sodium acetate (pH 5.0), 1 M GuHCl,
3 M urea, 150 mMNaCl, 10 mM EDTA for 4 days with contin-
ual orbital shaking. In replicating the work of Makarava et al.
[12], the methodology was followed as described with the sub-
stitution of the original hamster PrP for an equivalent murine
construct, PrP23–231. Similarly, the production of PMCA pro-
ducts described by Kim et al. [13] was carried out verbatim
with the substitution of hamster PrP constructs for murine
PrP91–231 and PrP23–231 as required and PMCA ’seeds’ of
PrPSc from RML-infected CD-1 mouse brain. In attempting to
reproduce the findings ofMa and co-workers [14], we subjected
murine PrP23–231 to the conditions described using 5% (w/v)
brain homogenate from normal CD-1 mice.
4.8. Transmission studies in mice
Samples containing recombinant mouse PrP (residues 23–231
or 91–231) or vehicle controls were diluted in sterile
Dulbecco’s phosphate-buffered saline lacking calcium ormag-
nesium ions and passed through a 25-gauge needle. CD1mice
were inoculated intracerebrally with 30 ml of solution contain-
ing between 15 and 0.015 mg of PrP. Thereafter, mice were
examined daily and killed if exhibiting signs of distress or
once a diagnosis of clinical prion disease was established[37]. At post-mortem brains from inoculated mice were
removed and divided sagittally, with half frozen and half
fixed in 10% formol-saline buffer. Clinical diagnosis of prion
disease can be confounded by non-specific conditions that
develop in mice as they age. We limited these confounding
effects by electively cullingmice after post-inoculation periods
of more than 600 days and confirming clinical prion disease
though neuropathological and immunohistochemical ana-
lyses. Mice were only scored positive if abnormal PrP was
demonstrated in brain.4.9. Neuropathological and immunohistochemical
analyses of mouse brain
Fixedmouse brainwas immersed in 98% formic acid for 1 h and
paraffin wax embedded. Serial sections (4 mm thick) were pre-
treated by boiling for 10 min in a low-ionic-strength buffer
(2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8)
before exposure to 98% formic acid for 5 min. Abnormal PrP
accumulation was examined using anti-PrP monoclonal anti-
body ICSM 35 (D-Gen Ltd, London) on an automated IHC
staining machine (Ventana Medical Systems Inc., Tucson,
Arizona) using proprietary secondary detection reagents
(Ventana Medical Systems Inc) before development with
303 diaminobenzedine tetrachloride as the chromogen [38]. Con-
ventionalmethodswere used forHarris haematoxylin and eosin
staining. Appropriate positive and negative controls were used
throughout. Photographs were taken on an ImageView digital
camera and composed with Adobe PHOTOSHOP.
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